A gift to the UCSF Department of Surgery can help physicians and scientist find treatments and cures for serious liver diseases such as hepatitis B & C, and liver cancer.
Professor of Clinical Medicine
Department of Medicine
Director of Viral Hepatitis Research in Liver Transplantation
| Academic Office Division of Gastroenterology 513 Parnassus Avenue, Room S-357 San Francisco, CA 94143-0358 Phone: (415) 476-2227 415-476-0659 norah.terrault@ucsf.edu | Liver Transplant Program 400 Parnassus Ave., Sixth Floor San Francisco, CA 94143 Phone: (415) 353-1888 Gastroenterology and Liver Faculty Practice 350 Parnassus Ave., Suite 410 San Francisco, CA 94143 Phone: (415) 353-2318 |
1994-95 Clinical Hepatology, Division of Gastroenterology, University of Toronto
1995-97 Research Hepatology, Division of Gastroenterology, UCSF Medical Center
Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.
Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.
My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.
Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation.